{"protocolSection":{"identificationModule":{"nctId":"NCT03816865","orgStudyIdInfo":{"id":"NOR-FIB2"},"organization":{"fullName":"Oslo University Hospital","class":"OTHER"},"briefTitle":"Fibrosis, Inflammation and Brain Health in Atrial Fibrillation.","officialTitle":"Fibrosis, Inflammation and Brain Health in Atrial Fibrillation. The Norwegian Atrial Fibrillation and Stroke Study","acronym":"NOR-FIB2"},"statusModule":{"statusVerifiedDate":"2020-08","overallStatus":"UNKNOWN","lastKnownStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-03-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-12-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2021-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2019-01-23","studyFirstSubmitQcDate":"2019-01-24","studyFirstPostDateStruct":{"date":"2019-01-25","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-03-02","lastUpdatePostDateStruct":{"date":"2021-03-03","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Anne Hege Aamodt","investigatorTitle":"Senior Consultant in Neurology","investigatorAffiliation":"Oslo University Hospital"},"leadSponsor":{"name":"Oslo University Hospital","class":"OTHER"},"collaborators":[{"name":"Ostfold Hospital Trust","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Protocol synopsis Sponsor: Oslo University Hospital Title: Fibrosis, inflammation and cerebral infarction in patients with atrial fibrillation Study Design: The study is an observational prospective study of atrial fibrillation patients undergoing direct-current cardioversion.\n\nPrimary Objective: To assess the prevalence and causes of new silent cerebral ischemic lesions after programmed direct-current cardioversion using diffusion-weighted sequences in brain MRI (DWMRI).\n\nSecondary Objectives:\n\nTo study the impact of inflammation measured by biomarkers and cardiac 18F-FDG-PET on the risk for new silent cerebral ischemic lesions after direct-current cardioversion for AF.\n\nTo assess the impact of fibrosis measured by biomarkers on the risk for new silent cerebral ischemic lesions after direct-current cardioversion for AF.\n\nTo assess cognitive and cerebral structural and metabolic changes after direct-current cardioversion for AF using cognitive assessments and cerebral and cardiac 18F-FDG-PET before and 12 months after treatment.\n\nNumber of Subjects: 50\n\nStudy Centers: Østfold Hospital Trust\n\nDuration of Study Participation:\n\n* Enrollment: 18 months\n* Follow-up period: 12 months\n* Total Study Duration: 30 months\n\nPrimary Endpoints:\n\n• Number of new small cerebral infarcts detected with DWMRI two weeks after direct current cardioversion.\n\nSecondary Endpoints:\n\n* Rate of AF recurrence within 1 year after direct current cardioversion\n* Change in levels of inflammation biomarkersfrom baseline to 12 months follow-up\n* Change in levels of fibrosis biomarkers from baseline to 12 months follow-up\n* Cognitive function at 12 months follow-up\n* Changes in uptake pattern on cerebral 18F-FDG-PET from baseline to 12 months follow-up\n* Changes in uptake pattern on cardiac 18F-FDG-PET from baseline to 12 months follow-up\n* Brain volume at 12 months follow-up\n* White matter volume 12 months follow-up\n* Grey matter volume 12 months follow-up\n* Cortical volume 12 months follow-up\n* RSI-derived diffusion parameters 12 months follow-up: fast apparent diffusion coefficient, extracellular water fraction, fractional anisotropy; free water fraction; intracranial volume; NAWM: normal appearing white matter; neurite density; RSI: restriction spectrum imaging; sADC: slow apparent diffusion coefficient;restricted fractional anisotropy; white matter lesions."},"conditionsModule":{"conditions":["Atrial Fibrillation","Stroke"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":50,"type":"ESTIMATED"}},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of new small cerebral infarcts detected with DWMRI two weeks after direct current cardioversion.","timeFrame":"2 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"1. Known atrial fibrillation\n2. Age \\<80 years\n3. CHA2DS2-VASc ≤ 4\n4. Planned direct-current cardioversion\n\nExclusion criteria:\n\n1. CHA2DS2-VASc \\>4\n2. Life expectancy less than 1 year\n3. Patient otherwise not eligible for the study or adherent for follow-up (eg nonresident) or has concurrent disease affecting outcome (e.g. multiple sclerosis, cancer)","sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients with atrial fibrillation undergoing direct-current cardioversion","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Anne Hege Aamodt, MD, PhD","role":"CONTACT","phone":"+47 95867270","email":"anhaam@ous-hf.no"},{"name":"Gudrun Høie, MD","role":"CONTACT","phone":"+47 97652459","email":"gudrun.anette.hoie@so-hf.no"}],"locations":[{"facility":"Oslo University Hospital","status":"RECRUITING","city":"Oslo","zip":"0424","country":"Norway","contacts":[{"name":"Anne Hege Aamodt, MD PhD","role":"CONTACT","phone":"+4723074976","email":"anne.hege.aamodt@ous-hf.no"}],"geoPoint":{"lat":59.91273,"lon":10.74609}},{"facility":"Østfold Hospital","status":"RECRUITING","city":"Sarpsborg","country":"Norway","contacts":[{"name":"Peter Andel","role":"CONTACT"}],"geoPoint":{"lat":59.28391,"lon":11.10962}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"},{"id":"D000007249","term":"Inflammation"}],"ancestors":[{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M9983","name":"Inflammation","asFound":"Inflammation","relevance":"HIGH"},{"id":"M8175","name":"Fibrosis","relevance":"LOW"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]}},"hasResults":false}